---
figid: PMC4367602__tlcr-02-03-152-f2
figtitle: Ligand stimulation of ERK and PI3K signaling in BRAFV600E melanomas
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4367602
filename: tlcr-02-03-152-f2.jpg
figlink: /pmc/articles/PMC4367602/figure/f2/
number: F2
caption: Ligand stimulation of ERK and PI3K signaling in BRAFV600E melanomas. In untreated
  melanomas, there is low signalability. However, hours after the ERK pathway is inhibited,
  the transduction of the signal is markedly potentiated (restored signalability).
  The induction of signalability could be blocked with the addition of an HER kinase
  inhibitor, such as neratinib ().
papertitle: Adaptive resistance to targeted therapies in cancer.
reftext: Rafael Rosell, et al. Transl Lung Cancer Res. 2013 Jun;2(3):152-159.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9139775
figid_alias: PMC4367602__F2
figtype: Figure
redirect_from: /figures/PMC4367602__F2
ndex: b1e31010-df10-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4367602__tlcr-02-03-152-f2.html
  '@type': Dataset
  description: Ligand stimulation of ERK and PI3K signaling in BRAFV600E melanomas.
    In untreated melanomas, there is low signalability. However, hours after the ERK
    pathway is inhibited, the transduction of the signal is markedly potentiated (restored
    signalability). The induction of signalability could be blocked with the addition
    of an HER kinase inhibitor, such as neratinib ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - HGF
  - IL6
  - SOS1
  - KRAS
  - HRAS
  - NRAS
  - CRLF1
  - CLCF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - RPTOR
  - SPRY2
  - EPHB2
  - MAPK1
  - MAPK3
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - DUSP6
  - EIF4EBP1
  - RPS6KB1
  - EIF4E
  - EIF4E2
  - EIF4E3
  - Cancer
  - Lung cancer
---
